CoChat

Targeting tumor–stromal interactions in triple-negative breast cancer using a human vascularized micro-tumor model

Open access

Published version of a preprint

The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.

Abstract

Triple-negative breast cancer (TNBC) is highly aggressive with limited available treatments. Stromal cells in the tumor microenvironment (TME) are crucial in TNBC progression; however, understanding the molecular basis of stromal cell activation and tumor-stromal crosstalk in TNBC is limited. To investigate therapeutic targets in the TNBC stromal niche, we used an advanced human in vitro microphysiological system called the vascularized micro-tumor (VMT). Using single-cell RNA sequencing, we revealed that normal breast tissue stromal cells activate neoplastic signaling pathways in the TNBC TME. By comparing interactions in VMTs with clinical data, we identified therapeutic targets at the tumor-stromal interface with potential clinical significance. Combining treatments targeting Tie2 signaling with paclitaxel resulted in vessel normalization and increased efficacy of paclitaxel in the TNBC VMT. Dual inhibition of HER3 and Akt also showed efficacy against TNBC. These data demonstrate the potential of inducing a favorable TME as a targeted therapeutic approach in TNBC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13058-023-01760-y

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Stromal cells freshly isolated from healthy breast tissue support microvascular network formation in VMO and VMT models. A Schematic of a single device unit with a single tissue chamber fed through microfluidic channels, 2 loading ports (L1–2), and uncoupled medium inlet and outlets (M1–2 and M3–4). A pressure regulator (PR) serves as a burst valve to release excess pressure from the tissue chamber during loading. B Left: Fluorescent image of a VMO established with stromal cells isolated freshly from histopathologically normal breast tissue. Vessels are shown in red and primary fibroblasts in blue. Right: Zoom view of a vascular network (red) perfused with 70 kDa dextran (cyan). C Left panel: VMO established with patient-derived breast tissue stromal cells. Vasculature shown in red. Middle panel: VMT established with MDA-MB-231 TNBC cells and patient-derived stromal cells. Note invasiveness of the tumor cells. Vasculature is red, tumor is green, and stromal cells are unlabeled. Right panel: VMT established with HCC1599 TNBC cells and patient-derived stromal cells. Vasculature is red, tumor is green, and stromal cells are unlabeled. Scale bar = 200 μm
Fig. 1 Stromal cells freshly isolated from healthy breast tissue support microvascular network formation in VMO and VMT models. A Schematic of a single device unit with a single tissue chamber fed through microfluidic channels, 2 loading ports (L1–2), and uncoupled medium inlet and outlets (M1–2 and M3–4). A pressure regulator (PR) serves as a burst valve to release excess pressure from the tissue chamber during loading. B Left: Fluorescent image of a VMO established with stromal cells isolated freshly from histopathologically normal breast tissue. Vessels are shown in red and primary fibroblasts in blue. Right: Zoom view of a vascular network (red) perfused with 70 kDa dextran (cyan). C Left panel: VMO established with patient-derived breast tissue stromal cells. Vasculature shown in red. Middle panel: VMT established with MDA-MB-231 TNBC cells and patient-derived stromal cells. Note invasiveness of the tumor cells. Vasculature is red, tumor is green, and stromal cells are unlabeled. Right panel: VMT established with HCC1599 TNBC cells and patient-derived stromal cells. Vasculature is red, tumor is green, and stromal cells are unlabeled. Scale bar = 200 μmCC BY · PubMed Central
Fig. 2 Single-cell RNA sequencing reveals transcriptomic shifts in triple-negative breast cancer VMTs and VMOs. A Schematic showing workflow of scRNA-seq. Matched VMO and VMT were established for TNBC cell lines MDA-MB-231 and HCC1599. Cells were isolated from each model and submitted for scRNA-seq. B UMAP of VMO matched to MDA-MB-231 VMT shows endothelial cells (ECs), fibroblasts, cycling cells and stromal cells are present as C shown with the expression of key marker genes. D UMAP of MDA-MB-231 VMT shows ECs, fibroblasts, stromal cells, cycling cells and tumors are present as E demonstrated with the expression of key marker genes. F UMAP of VMO matched to HCC1599 shows ECs, fibroblasts, and stromal cells are present as G demonstrated with the expression of key marker genes. H UMAP of HCC1599 VMT shows ECs, fibroblasts, stromal cells, and tumors are present as I shown with the expression of key marker genes. J Integrated dataset containing all cells from the VMO (MDA-MB-231), VMO (HCC1599), MDA-MB-231 VMT and HCC1599 VMT. K Proportions of different cell types from each dataset. L Heatmap showing top 5 DEGs from each cell type from each dataset in the integrated space
Fig. 2 Single-cell RNA sequencing reveals transcriptomic shifts in triple-negative breast cancer VMTs and VMOs. A Schematic showing workflow of scRNA-seq. Matched VMO and VMT were established for TNBC cell lines MDA-MB-231 and HCC1599. Cells were isolated from each model and submitted for scRNA-seq. B UMAP of VMO matched to MDA-MB-231 VMT shows endothelial cells (ECs), fibroblasts, cycling cells and stromal cells are present as C shown with the expression of key marker genes. D UMAP of MDA-MB-231 VMT shows ECs, fibroblasts, stromal cells, cycling cells and tumors are present as E demonstrated with the expression of key marker genes. F UMAP of VMO matched to HCC1599 shows ECs, fibroblasts, and stromal cells are present as G demonstrated with the expression of key marker genes. H UMAP of HCC1599 VMT shows ECs, fibroblasts, stromal cells, and tumors are present as I shown with the expression of key marker genes. J Integrated dataset containing all cells from the VMO (MDA-MB-231), VMO (HCC1599), MDA-MB-231 VMT and HCC1599 VMT. K Proportions of different cell types from each dataset. L Heatmap showing top 5 DEGs from each cell type from each dataset in the integrated spaceCC BY · PubMed Central
Fig. 3 VMTs recapitulate the tumor microenvironment and tumor–stromal signaling pathways of clinical TNBC. A Integration of VMT HCC1599 and VMT MDA-MB-231 with clinical datasets from three different papers reveals numerous cell types found in patients, including immune cells. B Subset shows distribution of datasets in the integrated dimensional space. C Proportion of each cell type found in each dataset. D Integration of only the cell types found in the VMT E shows that the VMT maps well to patient data. F Angiopoietin-1 receptor (TEK/Tie2) cell–cell communication comparing the strength of the signaling between the VMO and VMT + clinical samples. Sender = cell type that produces the ligand, Receiver = cell type that produces the receptor. G Expression of TEK and TEK ligand angiopoietin like 1 (ANGPTL1) in the integrated dataset. Each bar refers to the expression in a single cell. H Erb-B2 Receptor Tyrosine Kinase 3 (ERBB3/HER3) cell–cell communication comparing the strength of the signaling between the VMO and VMT + clinical samples. I Expression of ERBB3 and ERBB3 ligand amphiregulin (AREG) in the integrated dataset
Fig. 3 VMTs recapitulate the tumor microenvironment and tumor–stromal signaling pathways of clinical TNBC. A Integration of VMT HCC1599 and VMT MDA-MB-231 with clinical datasets from three different papers reveals numerous cell types found in patients, including immune cells. B Subset shows distribution of datasets in the integrated dimensional space. C Proportion of each cell type found in each dataset. D Integration of only the cell types found in the VMT E shows that the VMT maps well to patient data. F Angiopoietin-1 receptor (TEK/Tie2) cell–cell communication comparing the strength of the signaling between the VMO and VMT + clinical samples. Sender = cell type that produces the ligand, Receiver = cell type that produces the receptor. G Expression of TEK and TEK ligand angiopoietin like 1 (ANGPTL1) in the integrated dataset. Each bar refers to the expression in a single cell. H Erb-B2 Receptor Tyrosine Kinase 3 (ERBB3/HER3) cell–cell communication comparing the strength of the signaling between the VMO and VMT + clinical samples. I Expression of ERBB3 and ERBB3 ligand amphiregulin (AREG) in the integrated datasetCC BY · PubMed Central
Fig. 4 Targeting dysregulated tumor–stromal signaling in MDA-MB-231 VMT and HCC1599 VMT improves therapeutic responses. A Bar plot showing relative fold change compared to control for different vascular morphometry measurements of MDA-MB-231 TNBC-associated vessel response to razuprotafib 10 nM and 100 nM dose administered in the VMT on day 5 of culture for 48 h. B Fold change in average vessel length in MDA-MB-231 VMT over the course of 6 days post-treatment with 10 nM razuprotafib. C Fold change in vessel lacunarity in MDA-MB-231 VMT over the course of 6 days post-treatment with 10 nM razuprotafib. D Fold change in vessel percent area in MDA-MB-231 VMT over the course of 6 days post-treatment with 10 nM razuprotafib. E Fold change in vascular perfusion with 70 kDa fluorescent dextran in MDA-MB-231 VMT 24 h post-treatment with 10 nM razuprotafib. F Fluorescent micrographs showing MDA-MB-231 VMT with and without razuprotafib 10 nM, with tumors in green and vessels in red. VMT are perfused on day 6 with 70 kDa fluorescent dextran (shown in cyan). G Fold change in average vessel length, H vessel percent area, I vessel lacunarity and (J) tumor growth in treated MDA-MB-231 VMT. K Fluorescent micrographs showing control, L paclitaxel-treated, M razuprotafib-treated, N and combination treated MDA-MB-231 VMT as overlay and vessel only images. O Fold change in tumor growth in treated HCC1599 VMT. P Fluorescent micrographs showing control, Q sapitinib-treated, R MK2206-treated, and S combination treated HCC1599 VMT. Note that stromal cells are present in the VMT but are not fluorescently labeled. *p<0.05, **p<0.01, ***p<0.001
Fig. 4 Targeting dysregulated tumor–stromal signaling in MDA-MB-231 VMT and HCC1599 VMT improves therapeutic responses. A Bar plot showing relative fold change compared to control for different vascular morphometry measurements of MDA-MB-231 TNBC-associated vessel response to razuprotafib 10 nM and 100 nM dose administered in the VMT on day 5 of culture for 48 h. B Fold change in average vessel length in MDA-MB-231 VMT over the course of 6 days post-treatment with 10 nM razuprotafib. C Fold change in vessel lacunarity in MDA-MB-231 VMT over the course of 6 days post-treatment with 10 nM razuprotafib. D Fold change in vessel percent area in MDA-MB-231 VMT over the course of 6 days post-treatment with 10 nM razuprotafib. E Fold change in vascular perfusion with 70 kDa fluorescent dextran in MDA-MB-231 VMT 24 h post-treatment with 10 nM razuprotafib. F Fluorescent micrographs showing MDA-MB-231 VMT with and without razuprotafib 10 nM, with tumors in green and vessels in red. VMT are perfused on day 6 with 70 kDa fluorescent dextran (shown in cyan). G Fold change in average vessel length, H vessel percent area, I vessel lacunarity and (J) tumor growth in treated MDA-MB-231 VMT. K Fluorescent micrographs showing control, L paclitaxel-treated, M razuprotafib-treated, N and combination treated MDA-MB-231 VMT as overlay and vessel only images. O Fold change in tumor growth in treated HCC1599 VMT. P Fluorescent micrographs showing control, Q sapitinib-treated, R MK2206-treated, and S combination treated HCC1599 VMT. Note that stromal cells are present in the VMT but are not fluorescently labeled. *p<0.05, **p<0.01, ***p<0.001CC BY · PubMed Central
Fig. 5 Differential protein-level expression of drug targets is confirmed in VMOs and TNBC VMTs with and without treatment. A Tie2 staining of VMO and B MDA-MB-231 VMT shows differential expression. Vessels are red, tumor is green, and Tie2 protein is blue. Scale bars = 200 μm. C Zoom view of VMO stained with anti-Tie2 antibody. Scale bar = 100 μm D Zoom view of MDA-MB-231 VMT without treatment (control) stained with anti-Tie2 antibody. E Zoom view of MDA-MB-231 VMT treated with 10 nM razuprotafib and stained for Tie2. F Quantification of Tie2 protein expression in VMO, control MDA-MB-231 VMT, and razuprotafib-treated MDA-MB-231 VMT. G Phosphorylated ErbB3 (pHER3) staining of VMO and H HCC1599 VMT shows differential expression. Vessels are red, tumor is green, and pHER3 protein is blue. Scale bars = 200 μm. I Zoom view of VMO stained with anti-pHER3 antibody. Scale bar = 100 μm. J Zoom view of HCC1599 VMT without treatment (control) stained with anti-pHER3 antibody. K Zoom view of HCC1599 VMT treated with 100 nM sapitinib and stained for pHER3. L Quantification of HER3 protein phosphorylation in VMO, control HCC1599 VMT, and sapitinib-treated HCC1599 VMT. M Secondary-only IgG control VMO. Scale bar = 200 μm. N Secondary-only IgG control MDA-MB-231 VMT. Scale bar = 200 μm. O Secondary-only IgG control HCC1599 VMT. Scale bar = 200 μm. ns not significant, ***p<0.0001
Fig. 5 Differential protein-level expression of drug targets is confirmed in VMOs and TNBC VMTs with and without treatment. A Tie2 staining of VMO and B MDA-MB-231 VMT shows differential expression. Vessels are red, tumor is green, and Tie2 protein is blue. Scale bars = 200 μm. C Zoom view of VMO stained with anti-Tie2 antibody. Scale bar = 100 μm D Zoom view of MDA-MB-231 VMT without treatment (control) stained with anti-Tie2 antibody. E Zoom view of MDA-MB-231 VMT treated with 10 nM razuprotafib and stained for Tie2. F Quantification of Tie2 protein expression in VMO, control MDA-MB-231 VMT, and razuprotafib-treated MDA-MB-231 VMT. G Phosphorylated ErbB3 (pHER3) staining of VMO and H HCC1599 VMT shows differential expression. Vessels are red, tumor is green, and pHER3 protein is blue. Scale bars = 200 μm. I Zoom view of VMO stained with anti-pHER3 antibody. Scale bar = 100 μm. J Zoom view of HCC1599 VMT without treatment (control) stained with anti-pHER3 antibody. K Zoom view of HCC1599 VMT treated with 100 nM sapitinib and stained for pHER3. L Quantification of HER3 protein phosphorylation in VMO, control HCC1599 VMT, and sapitinib-treated HCC1599 VMT. M Secondary-only IgG control VMO. Scale bar = 200 μm. N Secondary-only IgG control MDA-MB-231 VMT. Scale bar = 200 μm. O Secondary-only IgG control HCC1599 VMT. Scale bar = 200 μm. ns not significant, ***p<0.0001CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 83 references

Cited by

See all 24

Metadata

Authors
Hachey, S. J., Hatch, C. J., Gaebler, D., Mocherla, A., Nee, K., Kessenbrock, K., & Hughes, C. C. W.
Affiliations
University of California, Irvine (US)
Corresponding author
Hachey, Stephanie J.
Venue
Breast Cancer Research
Published
2024-01-05
Volume
26
Issue
1
Pages
5-5
ISSN
  • 1465-5411 (ISSN-L)
  • 1465-542X
OpenAlex
W4390616031
Cited by
24
References
81
Citations by year
2026: 8 · 2025: 8 · 2024: 8
FWCI
4.11
Type
journal article
Language
en
Open access
Licence
Locations
  • Breast Cancer Research (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Center for Advancing Translational Sciences (TR001415)
  • National Heart, Lung, and Blood Institute (T32HL116270)
  • National Cancer Institute, United States (U54CA217378)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Keywords
triple-negative breast cancer, tumor-stroma interactions, tumor microenvironment, Tie2 signaling, paclitaxel, HER3, AKT inhibition, vessel normalization, therapeutic target, single-cell RNA sequencing
MeSH terms
Breast, Humans, Signal Transduction, Stromal Cells, Paclitaxel, Tumor Microenvironment, Triple Negative Breast Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting tumor–stromal interactions in triple-negative breast cancer using a human vascularized micro-tumor model. https://app.cochat.ai/papers/10.1186/s13058-023-01760-y
The paper
Hachey, S. J., Hatch, C. J., Gaebler, D., Mocherla, A., Nee, K., Kessenbrock, K., & Hughes, C. C. W. (2024). Targeting tumor–stromal interactions in triple-negative breast cancer using a human vascularized micro-tumor model. Breast Cancer Research. https://doi.org/10.1186/s13058-023-01760-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.